Background Optimal management of exsanguinating pelvic fractures remains controversial. Our previous experience suggested that management decisions based on a defined algorithm were associated with a significant reduction in transfusion requirements and mortality. Based on these outcomes, a clinical pathway for the management of exsanguinating pelvic fractures was developed. The purpose of this study was to evaluate the impact of this pathway on outcomes. Methods Consecutive patients over 10 years with blunt pelvic fractures subsequent to the implementation of the clinical pathway were identified. Patients with hemodynamically unstable pelvic fractures are managed initially with a pelvic orthotic device (POD). For those with continued hemodynamic instability and no extra-pelvic source of hemorrhage, pelvic angiography was performed followed by elective pelvic fixation. Patients managed according to the pathway (PW) were compared to those patients whose management deviated from the pathway (DEV). Results 3467 patients were identified. 312 (9%) met entry criteria: 246 (79%) comprised the PW group and 66 (21%) the DEV group. Injury severity, as measured by ISS (35 vs 36, p=0.55), admission GCS (10 vs 10, p=0.58), admission BE (-7.4 vs -6.4, p=0.38), admission SBP (107 vs 104, p=0.53), and PRBC requirements during initial resuscitation (6.1 vs 6.6 units, p=0.22) were similar between the groups. POD use was 48% in the DEV group (p
from Emergency Medicine via xlomafota13 on Inoreader https://ift.tt/2BWDuSU
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Lack of standard definitions of primary and secondary (non)responders after RYGB and SG makes it impossible to compare the litera...
-
We aimed (1) to describe the characteristics of patient–ventilator asynchrony in a population of critically ill children, (2) to describe th...
-
Objective We examined whether teleconsultation from ambulances to a physician at an emergency medical communication center (EMCC) would incr...
-
AbstractIntroductionVascular trauma data have been submitted to the American Association for the Surgery of Trauma PROspective Observational...
-
FDA approves Elzonris for blastic plasmacytoid dendritic cell neoplasm https://www.mdedge.com/hematologynews/article/191723/rare-diseases/...
-
Publication date: December 2018 Source: The Journal of Emergency Medicine, Volume 55, Issue 6 Author(s): Adam Esch from Emergency Medi...
-
Note: Page numbers of article titles are in boldface type. from Emergency Medicine via xlomafota13 on Inoreader http://ift.tt/2aggaBB
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου